Companies ›Healthcare ›APTA.L

APTA.L — London Stock Exchange Advanced Medical Equipment & Technology

Aptamer Group PLC

$0,53

Open in Charts → Attach watcher ⌖

— —

GBp

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

1,8B GBp

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Aptamer Group PLC develops and commercializes aptamer-based diagnostic and therapeutic products for the healthcare industry.

Business. Aptamer Group PLC (APTA.L) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in the United Kingdom and is listed on the London Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryAdvanced Medical Equipment & Technology

ActivityHealthcare Equipment

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning APTA.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to APTA.L. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Aptamer Group PLC (APTA.L) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in the United Kingdom and is listed on the London Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryAdvanced Medical Equipment & Technology

ActivityHealthcare Equipment

AI synthesis

GENERATED

— missing data

Key takeaways

Aptamer Group PLC operates in the Advanced Medical Equipment & Technology industry with 92% classification confidence.
The company has a market capitalization of £191.76 million and 3.46 billion shares outstanding.
No liquidity metrics are available due to missing balance-sheet inputs and lack of going-concern language in source documents.
No profitability, growth, or segment data is available in the provided financial snapshot.
The company is assessed to have low dilution risk, but liquidity risk remains unassessable.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Annual

ANNUALFiled 2023-11-09

FY 2023 · Full-year highlights

Revenue £1.8M, −56,6% YoY; Operating income −216,7% YoY.

Revenue£1.8M−56,6 % YoY

Operating income-£8.2M−216,7 % YoY

Net income-£7.8M−274,4 % YoY

Free cash flow-£9.1M−328,4 % YoY

EPS—

Operating cash flow-£4.1M−71,1 % YoY

Financials

Income statement

Revenue£1.8M

Gross profit£540.0k

Operating income-£8.2M

Net income-£7.8M

Margins

Gross margin30.8%

Operating margin-465.6%

Net margin-447.3%

FCF margin-517.4%

Balance sheet

Total assets£2.8M

Total liabilities£2.4M

Total equity£304.0k

Cash & equivalents—

Long-term debt£1.1M

Cash flow

Operating cash flow-£4.1M

CapEx-£2.0M

Free cash flow-£9.1M

SBC—

P&L flow · revenue → net income

Highlights

▍Revenue £1.8M, −56,6% YoY
▍Operating income −216,7% YoY
▍Net income −274,4% YoY
▍Free cash flow −328,4% YoY
▍Net margin -447.3%

Valuation FY

Market price

$0,53

Market cap

$1.92B

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted

Source documents

Aptamer Group PLC Market data — financials · 2026-05-27

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

APTA.LCanonical

London Stock Exchange · GBp

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2023-11-09 09:57 UTCEARNINGSAnnual results — FY 2023 Revenue GBP 1.8M · Net GBP -7.8M

2022-10-18 07:00 UTCEARNINGSAnnual results — FY 2022 Revenue GBP 4.0M · Net GBP -2.1M

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread